Bleakley Financial Group LLC Has $1.46 Million Stock Holdings in Kenvue Inc. (NYSE:KVUE)

Bleakley Financial Group LLC increased its position in shares of Kenvue Inc. (NYSE:KVUE) by 35.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 68,352 shares of the company’s stock after buying an additional 17,770 shares during the quarter. Bleakley Financial Group LLC’s holdings in Kenvue were worth $1,459,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. AMF Tjanstepension AB grew its holdings in shares of Kenvue by 187.3% during the third quarter. AMF Tjanstepension AB now owns 120,477 shares of the company’s stock valued at $2,787,000 after buying an additional 78,540 shares during the last quarter. Mather Group LLC. lifted its position in Kenvue by 62.0% in the 3rd quarter. Mather Group LLC. now owns 6,857 shares of the company’s stock valued at $159,000 after acquiring an additional 2,625 shares in the last quarter. Atomi Financial Group Inc. acquired a new position in Kenvue during the 3rd quarter valued at about $212,000. Perpetual Ltd increased its holdings in Kenvue by 2.6% during the 3rd quarter. Perpetual Ltd now owns 25,380 shares of the company’s stock worth $587,000 after purchasing an additional 652 shares in the last quarter. Finally, Juncture Wealth Strategies LLC purchased a new stake in shares of Kenvue in the third quarter worth approximately $241,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

Shares of NYSE KVUE opened at $20.23 on Friday. The firm has a market cap of $38.79 billion, a price-to-earnings ratio of 36.78, a price-to-earnings-growth ratio of 2.05 and a beta of 1.45. The stock has a fifty day simple moving average of $21.61 and a two-hundred day simple moving average of $21.93. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. Analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be paid a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 4.05%. The ex-dividend date is Wednesday, February 12th. Kenvue’s payout ratio is currently 149.09%.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. Canaccord Genuity Group cut their target price on Kenvue from $27.00 to $24.00 and set a “buy” rating on the stock in a research report on Friday. Piper Sandler raised shares of Kenvue from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $21.00 to $26.00 in a report on Monday, January 6th. JPMorgan Chase & Co. increased their target price on shares of Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Royal Bank of Canada reissued a “sector perform” rating and set a $24.00 price target on shares of Kenvue in a research report on Monday, February 3rd. Finally, Bank of America upped their price objective on shares of Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, October 22nd. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, Kenvue currently has a consensus rating of “Hold” and a consensus price target of $23.00.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.